Helping Develop The World's First Drug For A Rare Disease Affecting Children

Syngene, a leading global CRO/CDMO, partnered with a U.S.-based rare disease company to develop and manufacture a first-in-class treatment for a rare disease affecting children.

Syngene successfully developed the manufacturing process for the drug and supplied the required quantities to assist the company during different phases of drug development (preclinical and clinical) and later for commercial manufacturing.

The company received authorization for the sale of the product in the E.U. This was followed by regulatory approvals for sale in the U.S. and U.K. With this, the product has become the first drug in the world to be approved for children suffering from the rare disease.